Chris J. Novotny

TL;DR: A new class of mTOR inhibitors is reported which overcomes resistance to existing first and second generation inhibitors and exploits the unique juxtaposition of two drug binding pockets to create a bivalent interaction that allows inhibition of these resistant mutants.

TL;DR: This study re-establishes mTOR as a central target in glioma and traces the failure of existing drugs to incomplete/nondurable inhibition of mTORC1 to RapaLink-1, a TORKi linked to rapamycin, with earlier-generation mTOR inhibitors.

TL;DR: The first structures of ULK1, in complex with multiple potent inhibitors, show features unique to the enzyme and will provide a path for the rational design of selective compounds as cellular probes and potential therapeutics.

TL;DR: A new class of mTOR inhibitor, RapaLink-1, that takes advantage of the juxtaposition of two drug binding pockets to create a bivalent interaction and overcomes resistance to existing first and second generation inhibitors.

TL;DR: The creation of a neo-substrate for farnesyltransferase is presented that prevents the alternative prenlation by geranylgeranyltransferase and mislocalizes oncogenic K-Ras in cells.